Published by Josh White on 21st April 2026
(Sharecast News) - Avacta Therapeutics shares were rising on Tuesday, after new data presented at the American Association for Cancer Research (AACR) 2026 annual meeting highlighted the favourable profile of its AVA6103 candidate and the broader potential of its 'preCISION' tumour-targeted delivery platform.